scholarly journals Prognostic Factors and Metastatic Patterns in Primary Myxoid/Round-Cell Liposarcoma

Sarcoma ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-10 ◽  
Author(s):  
J. Haniball ◽  
V. P. Sumathi ◽  
L.-G. Kindblom ◽  
A. Abudu ◽  
S. R. Carter ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Local Recurrence ◽  
Adjuvant Radiotherapy ◽  
Surgical Excision ◽  
Round Cell ◽  
Cell Component ◽  
Adverse Prognostic Factor ◽  
Metastatic Patterns ◽  
Disease Specific

Background. This study aimed to investigate prognostic factors for patients with myxoid/round-cell liposarcoma (MRCLS), in particular the significance of the round cell component, and to identify metastatic patterns as well as possibly suggest a suitable strategy for followup.Methods. Clinical, morphologic, and follow-up data from 160 patients with MRCLS was reviewed and statistically analysed.Results. Of 130 tumours with the round cell component evaluated, 61 had no round cell component, 27 had <5% round cell component, and 42 had >5%. All patients underwent surgical excision, 15 requiring amputation. 107 patients received adjuvant radiotherapy. Local recurrence occurred in 19 patients (12%), predominantly in patients with marginal or intralesional margins and a round cell component. Overall disease specific survival was 75% at 5 years and 56% at 10 years and was related to the proportion of round cell component. Of 52 patients who developed metastases, 38 (73%) had purely extrapulmonary metastases. We could not identify any factors predicting the site of metastases developing.Conclusions. The occurrence of any round cell component is the most important adverse prognostic factor for patients with MRCLS; patients with >5% round cell component are at higher risk of local recurrence, metastasis and tumour-related death and should be considered for adjuvant radiotherapy and possibly chemotherapy. The best method of monitoring extrapulmonary metastases remains to be established.

scholarly journals Dermatofibrosarcoma Protuberans: Retrospective Single Center Analysis Over 16 Years

2018 ◽  
Vol 6 (1) ◽  
pp. 35-37
Author(s):  
Uwe Wollina ◽  
Dana Langner ◽  
Jacqueline Schönlebe ◽  
Katlein França ◽  
Torello Lotti ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
High Risk ◽  
Local Recurrence ◽  
Three Dimensional ◽  
Dermatofibrosarcoma Protuberans ◽  
Surgical Excision ◽  
Metastatic Spread ◽  
Single Center ◽  
Emerging Treatments ◽  
Margin Control

Dermatofibrosarcoma protuberans (DFSP) is rare mesenchymal neoplasia with a high risk of local recurrence but a low risk of metastatic spread. Tumor cells express CD34 and show a characteristic translocation t(17;22)(q22;q13). We analysed the documented cases at the Department of Dermatology and Allergology between 08/2001 and 08/2017. The diagnosis had been confirmed by histology and immunohistology in all cases. We identified four adults and a pediatric patient with DFSP. All patients were treated by wide surgical excision and controlled by three-dimensional histologic margin control. We observed no recurrence and no metastatic spread. We discuss prognostic factors and emerging treatments.

Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group.

1996 ◽  
Vol 14 (3) ◽  
pp. 869-877 ◽  
Author(s):  
J M Coindre ◽  
P Terrier ◽  
N B Bui ◽  
F Bonichon ◽  
F Collin ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Adjuvant Chemotherapy ◽  
Local Recurrence ◽  
Tumor Size ◽  
Adjuvant Radiotherapy ◽  
Tumor Depth ◽  
Cancer Centers ◽  
Grade 3 ◽  
Metastatic Risk ◽  
Deep Location

PURPOSE To define the prognostic factors in adult patients with locally controlled soft tissue sarcoma (STS) and to determine which patients should be considered for adjuvant treatment. PATIENTS AND METHODS Five hundred forty-six patients with a nonmetastatic and locally controlled STS, collected in a cooperative data base by the French Federation of Cancer Centers (FNCLCC) Sarcoma Group from 1980 and 1989, were studied. Histologic slides of all patients were collegially reviewed. Initial treatment consisted of complete tumor resection with amputation in only 4% of the patients. Adjuvant radiotherapy was administered to 57.9% and adjuvant chemotherapy to 31%. Relationships between tumor characteristics were analyzed, and univariate and multivariate analyses were performed using Cox models for the hazards rate of tumor mortality, development of distant metastasis, and strictly local recurrence. RESULTS Unfavorable characteristics with an independent prognostic value for tumor mortality were: grade 3 (P = 3 x 10(-10)), male sex (P = 1.5 x 10(-5)), no adjuvant chemotherapy (P = 5.4 x 10(-5)), tumor size > or = 5 cm (P = 3.8 x 10(-3)), and deep location (P = 4.6 x 10(-3)). Unfavorable characteristics for the development of distant metastasis were: grade 3 (P = 4 x 10(-12)), no adjuvant chemotherapy (P = 6.4 x 10(-4)), tumor size > or = 10 cm (P = 9.8 x 10(-4)), and deep location (P = 1.3 x 10(-3)). For the development of local recurrence, the unfavorable characteristics were: no adjuvant radiotherapy (P = 3.6 x 10(-6)), poor surgery (local excision) (P = 2 x 10(-4)), grade 3 (P = 7.6 x 10(-4)), and deep location (P = 10(-2)). Grade, depth, and tumor size were used to define groups of patients according to the metastatic risk. Adjuvant chemotherapy was beneficial in terms of overall survival and metastasis-free survival in grade 3 tumor patients only. Despite worse characteristics concerning tumor depth, tumor-node-metastasis (TNM) and American Joint Committee (AJC)/International Union Against Cancer (UICC) classifications and grade in patients with adjuvant radiotherapy, the latter experienced significantly fewer local recurrences than patients with no radiotherapy. CONCLUSION Grade, tumor depth, and tumor size could be used to select patients with a high metastatic risk, for which adjuvant chemotherapy could be beneficial.

Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years.

1989 ◽  
Vol 7 (9) ◽  
pp. 1239-1251 ◽  
Author(s):  
P P Rosen ◽  
S Groshen ◽  
P E Saigo ◽  
D W Kinne ◽  
S Hellman
Keyword(s):  
Prognostic Factors ◽  
Breast Carcinoma ◽  
Local Recurrence ◽  
Median Survival ◽  
Tumor Size ◽  
Stage I ◽  
Axillary Lymph ◽  
Axillary Lymph Node Metastases ◽  
Systemic Recurrence

Prognostic factors have been examined in 644 patients with tumor-node-metastasis (TNM) stage T1 breast carcinoma treated by mastectomy and followed for a median of 18.2 years. Overall, 148 patients (23%) died of recurrent breast carcinoma. Eighteen (3%) were alive with recurrent disease and 478 (74%) were alive or died of other causes without recurrence. Unfavorable clinicopathologic features were larger tumor size (1.1 to 2.0 cm v less than or equal to 1 cm), perimenopausal menstrual status, the number of axillary lymph node metastases, poorly differentiated grade, presence of lymphatic tumor emboli (LI) in breast tissue near the primary tumor, blood vessel invasion (BVI), and an intense lymphoplasmacytic reaction around the tumor. Median survival after recurrence for the entire series was 2 years. This was not significantly influenced by tumor size, the number of axillary nodal metastases, the type of treatment for recurrence, or the interval to recurrence. The proportions surviving 5 and 10 years after recurrence were 17% and 5%, respectively. Among T1N0M0 cases, the chance of a local recurrence was 2.8% within 20 years. Median survival of T1N0M0 cases after local recurrence (4.5 years) was significantly longer than after systemic recurrence (1.5 years). A similar trend (3.7 v 2.0 years), not statistically significant, was seen in T1N1M0 patients, who had a 6.5% chance of local recurrence within 20 years. Median survival following systemic recurrence detected 10 or more years after diagnosis in T1N0M0 and in T1N1M0 patients was significantly longer than the median survival for systemic recurrences found in the first decade of follow-up. This difference did not apply following local recurrence in either T1N0M0 or T1N1M0 cases. It is evident that patients with T1 breast carcinoma can be subdivided into differing prognostic groups and this must be taken into account when considering the role of adjuvant chemotherapy for stage I disease. Systemic adjuvant treatment may prove to be beneficial for patients with unfavorable prognostic factors, while women with an especially low risk for recurrence (eg, T1N0M0 tumor 1.0 cm or less) might be spared such treatment.

Nasal haemangiopericytoma: report of two cases with literature review

1999 ◽  
Vol 113 (3) ◽  
pp. 199-206 ◽  
Author(s):  
Rémi Marianowski ◽  
Michel Wassef ◽  
Philippe Herman ◽  
Partice Tran Ba Huy
Keyword(s):  
Local Recurrence ◽  
Literature Review ◽  
Paranasal Sinuses ◽  
Surgical Excision ◽  
Lateral Rhinotomy ◽  
Vascular Tumour ◽  
Wide Surgical Excision ◽  
Incomplete Removal ◽  
Midfacial Degloving

AbstractHaemangiopericytoma (HPC) is a rare vascular tumour produced by proliferation of pericytes. One hundred and thirty-three cases of HPC have been reported in the nose and the paranasal sinuses. We present two more cases. Wide surgical excision via lateral rhinotomy, midfacial degloving, or endonasal removal is the treatment of choice. Radiotherapy has been used post-operatively in cases of incomplete removal. Life-long follow-up is required to evaluate local recurrence and late metastases.

Chondrogenic neoplasms of the nasal cavity

1987 ◽  
Vol 101 (5) ◽  
pp. 500-505 ◽  
Author(s):  
O. E. El-Silimy ◽  
L. Harvey ◽  
M.R.C. Path ◽  
P. J. Bradley
Keyword(s):  
Local Recurrence ◽  
Nasal Cavity ◽  
Initial Treatment ◽  
Distant Metastases ◽  
Surgical Excision ◽  
Natural Course ◽  
Facial Skeleton ◽  
Histological Differentiation

Chondrogenic neoplasms of the nasal cavity are rare. Clinically, presentation is often late, with expansion and destruction of the middle facial skeleton. Local radical surgical excision is the preferred treatment, with regular life-long follow-up. Risk of local recurrence and distant metastases may Qccur many years after initial treatment. All chondrogenic tumours should be carefully followed up because the natural course of the disease may not match the histological differentiation.

Retrospective analysis of clinical characteristics and prognostic factors of neuroendocrine carcinoma of the gynecologic tract: A preliminary report of ten years follow-up.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e18001-e18001
Author(s):  
Y Zhang ◽  
J Yang ◽  
Qy Li ◽  
Zg Zhang ◽  
MJ Sun ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Neuroendocrine Carcinoma ◽  
Adjuvant Radiotherapy ◽  
Clinical Characteristics ◽  
Treatment Modalities ◽  
Cervix Uteri ◽  
Maximum Diameter ◽  
Ca 125 ◽  
Initial Symptoms

e18001 Background: To investigate the clinical characteristics and prognostic factors of neuroendocrine carcinoma of the gynecologic tract (NECGT). Methods: Patients with NECGT diagnosed during 2010 to 2019 were enrolled in this retrospective study. Clinical parameters were calculated, including age, childbearing history, initial symptoms, blood indexs, International Federation of Gynaecology and Obstetrics (FIGO) stages, treatment modalities and survival data. The cut-off values of parameters were screened by receiver-operating characteristic (ROC) curves and their significance was assessed by multivariate logistic regression. Results: We indentified forty five NECGT patients available with the median follow-up time of 5.5 months (9.7±1.98 months). 42 cases (93.3%) originated from cervix uteri, 2 cases (4.4%) from vagina and 1 case (2.2%) from fallopian tube. Irregular vaginal bleeding was the most frequent symptom at the first visit accounting for 75.6%. FIGO stages I to IV distributions were 16 (35.6%), 15 (33.3%), 6 (13.3%), and 8 patients (17.8%). Squamous carcinoma (16.7%) and adenocarcinoma (11.9%) were the common mixed pathological types. 66.7% patients underwent radical surgery, almost all of which received 4-6 cycles adjuvant chemotherapy and half followed by radiation therapy. While data analysis showed that adjuvant radiotherapy could not bring additional survival benefits (p = 0.523). The median PFS of enrolled patients was 14 months (1-78months). Pelvic recurrence (66.7%) and lymphatic metastasis (52.6%) were the main failure patterns. In multivariate analysis, leukocyte count (HR = 0.068, 95%CI: 0.007-0.673, p = 0.021), neutrophil-to-leukocyte ratio (HR = 0.151, 95%CI: 0.024-0.95, p = 0.044), lactic dehydrogenase (LDH) (HR = 6.632, 95%CI: 1.31-33.569, p = 0.022) and carbohydrate antigen-ca 125 (CA-125) (HR = 7.173, 95%CI: 1.25-41.06, p = 0.027) were the independent prognostic factors of PFS. In addition, age at natural menopause (ANM) later than 51.5years (p = 0.009) and an optimal maximum diameter > 62.1mm (p = 0.002) were closely related with poor survival. Conclusions: NECGT is a rare malignant tumor of female genital system. Surgery combined with chemotherapy is the essential treatment, addition of adjuvant radiotherapy did not improve survival. More high-quality clinical trials are needed to provide powerful evidence.

Prognostic factors in dogs with osteosarcomas of the flat or irregular bones

1995 ◽  
Vol 31 (4) ◽  
pp. 321-326 ◽  
Author(s):  
AS Hammer ◽  
FR Weeren ◽  
SE Weisbrode ◽  
SL Padgett
Keyword(s):  
Body Weight ◽  
Prognostic Factors ◽  
Local Recurrence ◽  
Survival Time ◽  
Medical Records ◽  
Median Survival Time ◽  
Surgical Excision ◽  
Survival Times ◽  
Anatomic Site ◽  
Common Cause

The medical records of 45 dogs with histopathologically confirmed osteosarcomas arising from flat or irregular bones were reviewed. Thirty-five percent of the dogs eventually developed metastases. Telangectatic tumors and tumors arising from the rib and scapula had the highest prevalence of metastases. Survival times were short, with an overall median survival time of 120 days. Anatomic site, body weight, and completeness of surgical excision were found to be prognostic factors. Dogs with mandibular osteosarcomas in this study had shorter survival times than those times recently reported. 21 Local recurrence was the most common cause of death or euthanasia in this population of dogs.

Clinical Outcome for MCTs of Canine Pinnae Treated with Surgical Excision (2004–2008)

2014 ◽  
Vol 50 (3) ◽  
pp. 187-191 ◽  
Author(s):  
Timothy M. Schwab ◽  
Catherine Popovitch ◽  
John DeBiasio ◽  
Michael Goldschmidt
Keyword(s):  
Local Recurrence ◽  
Surgical Excision ◽  
Tumor Grade ◽  
Published Data ◽  
Disease Free Interval ◽  
Mast Cell Tumors ◽  
Grade 3 ◽  
Record Review ◽  
Disease Free

Canine mast cell tumors (MCTs) are the most common cutaneous neoplasm in the dog. It has been suggested that MCT in certain locations may behave in a more biologically aggressive fashion than MCTs located in others; however, no published data are available for MCTs of canine pinnae treated with surgical excision. A retrospective study of 28 animals with surgical excision of MCTs of pinnae was completed with a medical record review and follow-up questionnaire to the operating veterinarian. The effect of tumor grade, clean or dirty excision, cartilage penetration, and mitotic index (MI) on local recurrence and survival time (ST) was evaluated. There was local recurrence in one dog with a grade 2 MCT and in seven of eight dogs with grade 3 MCTs. The median ST of animals with grade 1 and 2 MCTs was not reached, whereas the median ST of animals with grade 3 MCTs was 10 mo. There was no statistical association between histologically clean and dirty margins and either local recurrence or ST. A prolonged disease free interval without local recurrence may be achieved with local excision of grade 1 and 2 MCTs. Animals with grade 3 MCTs had a uniformly poor outcome with short times to local recurrence and death.

scholarly journals Denosumab: A potential new treatment option for recurrent Aneurysmal Bone Cyst of the spine

SICOT-J ◽  
2019 ◽  
Vol 5 ◽  
pp. 10 ◽  
Author(s):  
Arvind G. Kulkarni ◽  
Ankit Patel
Keyword(s):  
Local Recurrence ◽  
Human Monoclonal Antibody ◽  
Bone Cyst ◽  
Surgical Excision ◽  
Long Term Results ◽  
Osteolytic Lesions ◽  
Short Period ◽  
New Treatment

ABCs are expansile osteolytic lesions typically containing blood-filled spaces separated by fibrous septae. Standard treatment includes surgical resection or curettage and packing; however, for some spinal lesions, the standard approach is not optimal. One therapeutic strategy is to treat spinal ABC with an agent that targets a pathway that is dysregulated in a disease with similar pathophysiology. Denosumab, a human monoclonal antibody to RANKL is effective in the treatment of GCT's. Spinal ABCs are a therapeutic challenge and local recurrence is a concern. We report a case of aggressive recurrent ABC of dorsal spine in a 14-year old female with progressive neurologic deficit who underwent surgical excision and decompression with a recurrence in a short period for which a decompression and fixation was done. She had a recurrence after an asymptomatic period of 6 months and neurologic worsening. Having ruled out use of embolization and radiotherapy, a remission was achieved by treatment with Denosumab using the regimen for GCTs for a duration of 6 months. Follow-up MRI and CT scans at 24 months following inception of Denosumab depicted complete resolution and no recurrence. We conclude that Denosumab can result in symptomatic and radiological improvement in the recurrent locally aggressive ABC and may be useful in selected cases. Long-term results are mandatory to confirm the efficacy of Denosumab and to evaluate local recurrence after stopping Denosumab.

Sign in / Sign up

Export Citation Format

Share Document